Axonics Modulation Technologies

01 / WHAT IT BUILT

What the company did

Axonics Modulation Technologies was an Irvine, California-based medical device company focused on urology. It pioneered enhancements to sacral neuromodulation (SNM) therapy for bladder and bowel dysfunction - its rechargeable and recharge-free SNM systems received FDA approval in 2019 - and added urethral bulking for women with stress urinary incontinence by acquiring Bulkamid in 2021. The company went public on Nasdaq (AXNX) in 2018 and, after a patent victory over Medtronic in 2024, was acquired by Boston Scientific in November 2024 for an equity value of approximately $3.7 billion.

03 / EVENT HISTORY

Events in the structured record

1. 2013
   Founded

   Axonics was founded in Irvine, California to develop advanced solutions for incontinence, as later described by CEO Raymond Cohen as a ten-year journey from founding.

2. 2018
   Nasdaq IPO

   The company completed an initial public offering on Nasdaq under the ticker AXNX, raising $138 million.

3. 2019
   FDA approval

   Axonics received FDA approval for its sacral neuromodulation (SNM) system, entering the market against incumbent Medtronic with rechargeable and recharge-free implantable devices.

4. 2021
   Acquired Bulkamid

   The company expanded into urethral bulking for stress urinary incontinence by acquiring Bulkamid for $141.25 million upfront.

5. 2024
   Acquired by Boston Scientific

   In January 2024 Axonics announced a definitive agreement to be acquired by Boston Scientific for $71 per share in cash, an equity value of about $3.7 billion; the deal closed in November 2024, making Axonics a wholly owned subsidiary.